Terms: = Endocrine gland cancer AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2 AND Treatment
103 results:
1. Therapeutic potential of targeting nrf2 by panobinostat in pituitary neuroendocrine tumors.
Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
[TBL] [Abstract] [Full Text] [Related]
2. ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and Pancreatic cancer Cells.
Takasaki T; Hamabe Y; Touchi K; Khandakar GI; Ueda T; Okada H; Sakai K; Nishio K; Tanabe G; Sugiura R
Oxid Med Cell Longev; 2024; 2024():7683793. PubMed ID: 38500550
[TBL] [Abstract] [Full Text] [Related]
3. Targeting nrf2 to treat thyroid cancer.
Gong Z; Xue L; Li H; Fan S; van Hasselt CA; Li D; Zeng X; Tong MCF; Chen GG
Biomed Pharmacother; 2024 Apr; 173():116324. PubMed ID: 38422655
[TBL] [Abstract] [Full Text] [Related]
4. Synergistic suppression of ovarian cancer by combining nrf2 and GPX4 inhibitors: in vitro and in vivo evidence.
Li N; Jiang X; Zhang Q; Huang Y; Wei J; Zhang H; Luo H
J Ovarian Res; 2024 Feb; 17(1):49. PubMed ID: 38396022
[TBL] [Abstract] [Full Text] [Related]
5. β-Sitosterol targets ASS1 for nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN/PI3K/AKT signaling pathway in ovarian cancer.
Wang H; Liu J; Zhang Z; Peng J; Wang Z; Yang L; Wang X; Hu S; Hong L
Free Radic Biol Med; 2024 Mar; 214():137-157. PubMed ID: 38364944
[TBL] [Abstract] [Full Text] [Related]
6. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/nrf2 axis in pancreatic cancer.
Tuerhong A; Xu J; Wang W; Shi S; Meng Q; Hua J; Liu J; Zhang B; Yu X; Liang C
Surgery; 2024 May; 175(5):1264-1275. PubMed ID: 38302326
[TBL] [Abstract] [Full Text] [Related]
7. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas.
Bildik G; Gray JP; Mao W; Yang H; Ozyurt R; Orellana VR; De Wever O; Carey MS; Bast RC; Lu Z
Autophagy; 2024 Mar; 20(3):675-691. PubMed ID: 38169324
[TBL] [Abstract] [Full Text] [Related]
8. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic cancer.
Kim MJ; Kim HS; Kang HW; Lee DE; Hong WC; Kim JH; Kim M; Cheong JH; Kim HJ; Park JS
Cells; 2023 Oct; 12(20):. PubMed ID: 37887353
[TBL] [Abstract] [Full Text] [Related]
9. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
10. Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing nrf2 activity.
Ruan Q; Wen C; Jin G; Yuan Z; Yang X; Wen Z; Huang G; Li G; Deng J; Bai Y
Phytomedicine; 2023 Sep; 118():154990. PubMed ID: 37494874
[TBL] [Abstract] [Full Text] [Related]
11. Potentiation of Cisplatin Cytotoxicity in Resistant Ovarian cancer SKOV3/Cisplatin Cells by Quercetin Pre-treatment.
Hasan AA; Kalinina E; Nuzhina J; Volodina Y; Shtil A; Tatarskiy V
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446140
[TBL] [Abstract] [Full Text] [Related]
12. A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis.
König P; Zhulenko R; Suparman E; Hoffmeister H; Bückreiß N; Ott I; Bendas G
Cancer Chemother Pharmacol; 2023 Jul; 92(1):57-69. PubMed ID: 37272932
[TBL] [Abstract] [Full Text] [Related]
13. Tripterygium glycosides reverse chemotherapy resistance in ovarian cancer by targeting the nrf2/GPX4 signal axis to induce ferroptosis of drug-resistant human epithelial ovarian cancer cells.
Ma B; Zhong Y; Chen R; Zhan X; Huang G; Xiong Y; Tan B
Biochem Biophys Res Commun; 2023 Jul; 665():178-186. PubMed ID: 37163938
[TBL] [Abstract] [Full Text] [Related]
14. Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer.
Yue W; Yupeng G; Jun C; Kui J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8681-8689. PubMed ID: 37120435
[TBL] [Abstract] [Full Text] [Related]
15. CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma.
Wu N; Zhu D; Li J; Li X; Zhu Z; Rao Q; Hu B; Wang H; Zhu Y
J Endocrinol Invest; 2023 Aug; 46(8):1573-1587. PubMed ID: 36853491
[TBL] [Abstract] [Full Text] [Related]
16. Mechanical Regulation of Redox Balance via the Induction of the PIN1/nrf2/ARE Axis in Pancreatic cancer.
Liang C; Rong Z; Tuerhong A; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Shi S; Xu J
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834887
[TBL] [Abstract] [Full Text] [Related]
17. nrf2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8.
Anandhan A; Dodson M; Shakya A; Chen J; Liu P; Wei Y; Tan H; Wang Q; Jiang Z; Yang K; Garcia JG; Chambers SK; Chapman E; Ooi A; Yang-Hartwich Y; Stockwell BR; Zhang DD
Sci Adv; 2023 Feb; 9(5):eade9585. PubMed ID: 36724221
[TBL] [Abstract] [Full Text] [Related]
18. Cinchonine-induced cell death in pancreatic cancer cells by downregulating RRP15.
Liang F; Lv Y; Qiao X; Zhang S; Shen S; Wang C; Xu G; Zou X; Wang L; Zhang B
Cell Biol Int; 2023 May; 47(5):907-919. PubMed ID: 36682038
[TBL] [Abstract] [Full Text] [Related]
19. Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma.
Raninga PV; He Y; Datta KK; Lu X; Maheshwari UR; Venkat P; Mayoh C; Gowda H; Kalimutho M; Hooper JD; Khanna KK
Mol Ther; 2023 Mar; 31(3):729-743. PubMed ID: 36560881
[TBL] [Abstract] [Full Text] [Related]
20. Periplocin exerts antitumor activity by regulating nrf2-mediated signaling pathway in gemcitabine-resistant pancreatic cancer cells.
Bae ES; Byun WS; Ock CW; Kim WK; Park HJ; Lee SK
Biomed Pharmacother; 2023 Jan; 157():114039. PubMed ID: 36423542
[TBL] [Abstract] [Full Text] [Related]
[Next]
